23andMe DTC Breast and Ovarian Cancer Risk Test Misses Almost 90 Percent of BRCA Mutation Carriers | GenomeWeb Prem… https://t.co/nl4pDshQI9
2:17pm April 5th 2019 via Buffer
Probiotics, touted as good for the gut, may be trouble for immune system | Stat News https://t.co/2M6cy5jIZq
9:23am April 5th 2019 via Buffer
The Trump administration is forcing this health start-up that took Chinese money into a fire sale | CNBC… https://t.co/BbJ28EbpK7
8:34am April 5th 2019 via Buffer
AACR 2019 Day Two: Learning About the Microbiome in Immuno-Oncology | SeraCare blog https://t.co/bhTy2gDVDc
7:31am April 5th 2019 via Buffer
ICYMI: New post: Single-cell companies Mission Bio and Celsee Inc. at American Association for Cancer Research 2019… https://t.co/778fbZSA9q
7:10am April 5th 2019 via Hootsuite Inc.
@3DiMMUNE @iskander James Heath of the ISB.
9:53pm April 4th 2019 via Hootsuite Inc. in reply to 3DiMMUNE
Machine Learning in Medicine | NEJM $ https://t.co/tjfF4bFeT4
1:12pm April 4th 2019 via Buffer
Are PhDs just cheap labour for universities? | The Guardian https://t.co/d6HzpXmBZj
12:04pm April 4th 2019 via Buffer
Roche launches NAVIFY Mutation Profiler and NAVIFY Therapy Matcher to support comprehensive genomic profiling in ca… https://t.co/rJe8pXiVet
11:04am April 4th 2019 via Buffer
The Skills Companies Need Most in 2019 – And How to Learn Them | LinkedIn https://t.co/shkh46acIT 3 most-wanted “so… https://t.co/ncT995O75x
8:34am April 4th 2019 via Buffer
Resolution Bio Liquid Biopsy Outperforms Guardant Test in Lung Cancer Gene Fusion Detection | Genomeweb Premium https://t.co/kipUtLMKYC
7:31am April 4th 2019 via Buffer
Resolution Liquid Biopsy Assay Outperforms Guardant360 in Retrospective Non-Small Cell Lung Carcinoma Comparison Pi… https://t.co/jqdkQKvSZv
7:03pm April 3rd 2019 via Buffer
First Epigenetic Signature Test for Inherited Disorders to Launch in the US, Europe | GenomeWeb Premium https://t.co/KtDx51LLnE
6:09pm April 3rd 2019 via Buffer
NanoString Signs on AbCam to Supply Antibody Panels for Spatial Profiling Platform | GenomeWeb https://t.co/yi3QCjRNgB
5:14pm April 3rd 2019 via Buffer
AACR Meeting Opens With Focus on Personalized Cancer Care Through Technological Convergence | GenomeWeb https://t.co/D51XJRqOao
3:18pm April 3rd 2019 via Buffer
Resolving genetic heterogeneity in cancer | Nature Reviews Genetics ($) https://t.co/mv9E2olq1G
2:17pm April 3rd 2019 via Buffer
Inferring population dynamics from single-cell RNA-sequencing time series data | Nature Biotech ($) https://t.co/qJJmxfXsyZ
1:12pm April 3rd 2019 via Buffer
Digital medicine startups are booming. What are the side effects? | Fast Company https://t.co/SwiOpEQtmQ
12:04pm April 3rd 2019 via Buffer
Highly Profitable Medical Journal Says Open Access Publishing Has Failed. Right. | Forbes https://t.co/nZmS1wVMRo
11:04am April 3rd 2019 via Buffer
New post: Single-cell companies Mission Bio and Celsee Inc. at American Association for Cancer Research 2019 #AACR19 https://t.co/MO7jxEtM5y
7:20am April 3rd 2019 via WP to TWTR on Yuzuki.org
#AACR19 Q: Why do droplets not work as well? Adey: droplets gave a lot of doublets, less flexible. With microwells… https://t.co/v30hq2RzdE
3:52pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey Reads are falling in peaks; new data. Goal - sci-ATAC-seq, sci-HiC; sci-DNA; sci-RNA. Want to release protocols to the public.
3:48pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey 'Adapting it to something else is just what we do' (!) CelSee ATAC pool: new data shows it works. 10's… https://t.co/ZKjVn0lTU0
3:46pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey sci-ATAC involved a lot of barcoding; Celsee microwells the perfect time for them to try it. Physical… https://t.co/GYPecNXXdW
#AACR19 Adey '18 ref https://t.co/bq8Tk116rJ Hypermethylated at inhibitory DMRs, opposite at simulatory ones.
3:45pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey Beyond ATAC: the genome. '17 ref https://t.co/sdtSVJCaNL Removing unbound chr to get genome-wide seq, incl methylation
3:44pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey 2nd project: mouse model of PDAC tumorigenesis. sci-ATAC-seq, could ID 'topics' (shared regulatory gro… https://t.co/svqYfDWyhO
3:42pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey Pseudotemporal ordering: using Monocle (normally with RNA data). Look at global TF access. Not a lot i… https://t.co/1S2xQA85hk
3:39pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey 5 TNBC cell lines: were able to separate out cell lines and 2 different treatments. But what shared mechanisms?
3:38pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey sci-ATAC-Seq - append barcodes to single-cell. Combine, dilute to 20/well, index again. Get 1000's of profiles in expt
#AACR19 Adey Enhancer usage is cell-type specific. Transposase-based library prep to access open chromatin. Assay f… https://t.co/3USFQCNcLk
3:36pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey Shows '16 fig https://t.co/4jz2Ju7XCk "Just about says it all" - binary signal of regulatory element s… https://t.co/2foWibQfw2
3:35pm April 2nd 2019 via Twitter Web Client
#AACR19 Adey sci-ATAC-seq; sci-ATAC-seq in TNBC, PDAC; beyond it and porting to Celsee. ATAC-seq: focus on chromatin-accessible areas
3:33pm April 2nd 2019 via Twitter Web Client
#AACR19 Andrew Adey (OSHU) Single-cell omics with microwell miniaturization. Most sc studies are scRNA-seq. But - r… https://t.co/GsT3xeu3ft
3:32pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Concl: They want to offer test bundles/offerings to differentiate. Leverage high param CTC analys… https://t.co/zNLYtgf1W1
3:31pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Showing recovery of InCellDx BioINK kit results - maximizing CTC recovery. Sample prep - they hav… https://t.co/uKjAxD9Z8w
3:30pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson High PD-L1 exp and anueploidy correlated with tumor load. CTC prediction from primary tumor. Show… https://t.co/WUFxx165wF
3:28pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Found they can go to 1:1,000,000 cells 'highly linear'. Found high var in tumors.
3:25pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Gemini study: paired primary tumor/blood comparison. 30+ marker capabilities - Beckman Cytoflex Rx.
#AACR19 Patterson In 25 lung ca - PD-L1 increases as tumor cell clones increase. In prostate: have a 'ton of circ e… https://t.co/LxIPaTP5X5
3:24pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Simultaneous detection of protein, mRNA, and DNA. Shows PD-L1 expression as a function of DNA con… https://t.co/VWiQFbQmOh
3:21pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Epithelial cells (CK+) in urine: 6% InCellMax vs 30% Preservemyt rejection rate. Shows their menu… https://t.co/IyuH56zAF7
3:20pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson What drives this: InCellMax preservative; non-crosslinking; single-step in-situ hyb/FISH w/o prot… https://t.co/d0M83QurBz
3:18pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson InCellDx can use blood, urine. As they are Dx, InCellPrep is a class I to make a single-cell susp… https://t.co/G18GXDlHwi
3:17pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Tumors are highly heterogeneous; yet we put them in a blender. Originally: used Southerns to look… https://t.co/zN2NWNrTD3
3:16pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Think about the translation into the clinical realm. Personalizing of medicine: goes much deeper,… https://t.co/MABaUPimuD
3:15pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson Measuring HIV in plasma: viral load has 1000:1 ratio of non-infectious to infectious, 'the ultima… https://t.co/v8QiYgpEU9
#AACR19 Patterson InCellDx offers comprehensive, quantitative, simultaneous, and multiplexed. 'The cell is everything'.
3:14pm April 2nd 2019 via Twitter Web Client
#AACR19 Patterson (InCellDx) Single cell-by-cell diagnostics. Have been able to translate all reagents used via flo… https://t.co/Xj5MZmExh9
3:13pm April 2nd 2019 via Twitter Web Client
Celsee #AACR19 Ranade sc Cytometry, sc proteo-genomics, sc transcriptomics, also open platform.
3:12pm April 2nd 2019 via Twitter Web Client
